Barclays PLC Vigil Neuroscience, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Barclays PLC holds 44,613 shares of VIGL stock, worth $112,424. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,613

Previous 44,613 -0.0%

Holding current value

$112,424

Previous $152,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$2.92 - $4.65 $414 - $660	-142 Reduced 0.32%	44,613 $152,000
Q2 2024 Aug 14, 2024	SELL	$2.51 - $4.66 $171,385 - $318,189	-68,281 Reduced 60.41%	44,755 $179,000
Q1 2024 May 15, 2024	SELL	$2.68 - $3.63 $28,834 - $39,055	-10,759 Reduced 8.69%	113,036 $386,000
Q4 2023 Feb 15, 2024	BUY	$2.97 - $8.6 $57,038 - $165,163	19,205 Added 18.36%	123,795 $419,000
Q3 2023 Nov 07, 2023	SELL	$4.8 - $9.92 $1,497 - $3,095	-312 Reduced 0.3%	104,590 $564,000
Q2 2023 Aug 03, 2023	BUY	$8.11 - $10.54 $5,303 - $6,893	654 Added 0.63%	104,902 $986,000
Q1 2023 May 04, 2023	SELL	$8.77 - $12.7 $14,426 - $20,891	-1,645 Reduced 1.55%	104,248 $1.02 Million
Q4 2022 Feb 13, 2023	BUY	$8.74 - $15.99 $32,600 - $59,642	3,730 Added 3.65%	105,893 $1.32 Million
Q3 2022 Nov 03, 2022	BUY	$2.37 - $9.61 $1,142 - $4,632	482 Added 0.47%	102,163 $929,000
Q2 2022 Aug 12, 2022	SELL	$2.23 - $7.81 $2,435 - $8,528	-1,092 Reduced 1.06%	101,681 $262,000
Q1 2022 May 16, 2022	BUY	$7.03 - $17.29 $722,494 - $1.78 Million	102,773 New	102,773 $722,000

Others Institutions Holding VIGL

# of Institutions

Shares Held

28.2M

Call Options Held

Put Options Held

View Full List

About Vigil Neuroscience, Inc.

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $71.2M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

More about VIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account